AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02991417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDVAX
Study NCT03694444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMY-101
Description: C3 complement inhibitor
Study NCT03694444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: Placebo
Study NCT01601457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: 90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
Study NCT01601457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
Study NCT00284427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C
Description: IV Vitamin C given 2-3 times a week
Study NCT01537068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Description: Desvenlafaxine oral dose ranging from 50 to 100 mg/day
Study NCT01537068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo pills
Study NCT02044874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356-lorcaserin hydrochloride
Study NCT02044874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01289756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: clomiphene once 100 mg oral
Study NCT01289756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and paroxetine
Description: clomiphene 100mg and paroxetine 3x40mg
Study NCT01289756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and clarithromycin
Description: clomiphene 100mg and clarithromycin 9x500mg
Study NCT00312481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
Description: Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
Study NCT00312481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NA picosulfate magnesium citrate
Description: 150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.
Study NCT01895348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
Study NCT01895348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-remifentanil
Description: Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
Study NCT01895348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine-remifentanil
Description: Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
Study NCT04563806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI-guided surgery
Study NCT04563806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo spinal surgery
Study NCT01898143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Whole body vibration
Study NCT02918903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal caries removal
Description: the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
Study NCT02918903 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete caries removal
Description: the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
Study NCT02985073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veritas®
Description: Biologic mesh
Study NCT02985073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIGR®
Description: Non biologic mesh
Study NCT01210495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Axitinib \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
Study NCT01210495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
Study NCT01210495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
Study NCT01210495 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
Study NCT01446237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%
Description: over the counter acne system
Study NCT01046851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nopan
Description: Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
Study NCT04127084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 Inhibition
Description: Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
Study NCT01046851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a manner similar to the active comparator
Study NCT00588211 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: 45-minute individual interviews after the conclusion of their dental appointment
Study NCT00588211 — intervention group
Intervention type: BEHAVIORAL
Intervention: focus group
Description: A focus group of the preliminary cancer-related risk perception item pool.
Study NCT00588211 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Quantitative item analysis of the final item pool.
Study NCT00588211 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: A second confirmatory factor analysis.
Study NCT01117675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Hospital
Description: A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients
Study NCT01117675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care
Study NCT04590677 — intervention group
Intervention type: OTHER
Intervention: Samples required from group 1 (procedure within observational study)
Description: * Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs~* Daily Heart rate monitoring (only applicable to a subset of women in group 1)
Study NCT04590677 — intervention group
Intervention type: OTHER
Intervention: Samples required from group 2 (procedure within observational study)
Description: * Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs
Study NCT02464891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Study NCT02444364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Subjects will receive 90 tablets of 100mg sitagliptin
Study NCT06309420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryogenic treatment of warts (Pixie CO2)
Description: Treatment of common and plantar warts by cryotherapy treatment.
Study NCT06309420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryogenic treatment of warts (Wortie®)
Description: Treatment of common and plantar warts by cryotherapy treatment.
Study NCT01914575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping with the Acutus Medical System followed by Ablation
Study NCT01374932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airways pressure (CPAP)
Study NCT01829178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: Silymarin 420 mg in 3 divided dose plus standard chemotherapy
Study NCT01829178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets: 420 mg in 3 divided dose
Study NCT01829178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy
Description: All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
Study NCT01829178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
Study NCT04706806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: apple cider vinegar
Description: 2 tablespoons diluted in water taken twice daily with meals
Study NCT04706806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vinegar pill
Description: one pill taken daily
Study NCT00692107 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gray
Description: 68 Gy vs. 78 Gy
Study NCT00692107 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gray
Description: 68 Gy vs. 78 Gy
Study NCT03064100 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: Exclusion from the study
Study NCT00362713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
Study NCT02396303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Study NCT02396303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Study NCT01286168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (Dakin's Solution)
Description: 10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
Study NCT01286168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate disk
Description: Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
Study NCT01286168 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
Study NCT01286168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusive Adhesive Dressing
Description: A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
Study NCT04285515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42mg oral capsule
Study NCT04285515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo oral capsule
Study NCT02928770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nastent
Description: Use of the device while at home and in the sleep lab
Study NCT04500600 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04500600 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT01432561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine bitartrate
Description: 500 mg total, single dose taken orally on visits 2, 3 \& 4 which must occur within a 14 day period.
Study NCT03740529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral
Study NCT03740529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral
Study NCT03740529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV
Study NCT00868491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin, 5-fluorouracil
Description: docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
Study NCT00868491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
Study NCT00868491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab, cisplatin
Description: * cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~* cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)
Study NCT01332279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT01332279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT01332279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT01332279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01332279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01332279 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polyacrylamide gel electrophoresis
Description: Correlative studies
Study NCT01332279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01332279 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo EBRT
Study NCT01332279 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study NCT02813005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jet ventilation group
Description: MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
Study NCT02813005 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard ventilation group
Description: apnea made by the anesthesiologist to the request of the radiologist
Study NCT03556293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AKI Prevention Toolkit
Description: AKI Prevention Toolkit. Intervention: All sites will receive the AKI Prevention Toolkit including 3 core interventions: 1. Standardized order sets; 2. IV and oral fluids; and 3. Reduced contrast volume. The interventions adhere to the KDIGO guidelines and add interventions developed and tested in our pilot intervention to implement AKI preventive strategies.
Study NCT03556293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical Assistance (TA)
Description: Technical Assistance (TA). Intervention: TA will be offered to the 8 teams randomized to the TA condition and will receive the AKI Prevention Toolkit plus monthly technical calls independently. TA arms will include TA with and without automated surveillance reporting (ASR).
Study NCT03556293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Learning Collaborative (VLC)
Description: Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 8 teams and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator \[CAC\] and Systems Redesign). VLC arms will include VLC with and without automated surveillance reporting (ASR).
Study NCT03556293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated Surveillance Reporting (ASR)
Description: Automated Surveillance Reporting (ASR). Intervention: The ASR will be offered to 8 teams. In addition to either TA or VLC, ASR teams will receive automated monthly reports in the form of an dashboard focused on AKI outcome and preventative measures overtime. The ASR report will be customized to each team and each individual operator and linked to their national VA-CART registry.
Study NCT02407457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AFX EVAR AAA Graft System
Description: Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
Study NCT02407457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA Approved EVAR AAA Graft Systems
Study NCT04630249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to Women and Pregnant and Postpartum People
Description: Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to telemedicine mental health and substance use disorder treatment services.
Study NCT02789956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal vs. external cad cam co/cr framework
Study NCT02789956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal vs. external cad cam co/cr framework
Study NCT06157112 — intervention group
Intervention type: OTHER
Intervention: Lifestyle behaviour (exposure in a observational study)
Description: Lifestyle behaviour, including physical activity, sleep duration, alcohol consumption, smoking, cannabis and other illegal drugs
Study NCT00713661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TachoSil®
Description: Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.~Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy.
Study NCT00451295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
Study NCT00451295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
Study NCT01786824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydration strategy using saline
Description: For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
Study NCT04215185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial LIne
Description: Continuous non-invasive recording of CS6BP will be taken parallel to the recording of an invasive arterial line. ECG data recorded in the ICU will also be collected.
Study NCT01786824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydration strategy using saline
Description: For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
Study NCT01786824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydration strategy using sodium bicarbonate
Description: For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.